News on GlaxoSmithKline (Ticker: GSK) continually updated from thousands of sources around the net.
2 hrs ago | Value Line
Value Line offers a number of proprietary measures to help investors identify so-called conservative stocks, the most notable being the Safety Rank.
Trending on the Topix Network
6 hrs ago | Newsday
AstraZeneca has posted a drop in first quarter profits after its earnings were by hit by patents expiring on some of its older medicines.
The Aug. 12, 2005 file photo shows the logo of Swiss company Novartis in Basel, Switzerland.
The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.
Novartis and GlaxoSmithKline exchanged more than $20 billion in assets recently to reinforce their profitable divisions and eliminate their weaker businesses as drug manufacturers adjust to competition from generics and spending cuts in healthcare.
GlaxoSmithKline might be laying workers off but, others are hiring too! Check it out! GlaxoSmithKline's mutlibillion-dollar deal with Novartis announced Tuesday morning is expected to impact the drug company's workers in western Montgomery County the most.
While Novartis AG, GlaxoSmithKline and Eli Lilly are unclear about the long-term impact of deal on their India businesses, there is unlikely to be any direct or immediate impact.
GlaxoSmithKline Asia has slashed the price of fever and pain-relief pill Crocin Advance tablets across the country by around 50 per cent in order to conform to the price notified under DPCO, 2013.
A number of other analysts have also recently weighed in on GSK. Analysts at Zacks downgraded shares of GlaxoSmithKline plc from a "neutral" rating to an "underperform" rating in a research note on Friday, February 21st.
British drug giant GlaxoSmithKline will come under more pressure from prosecutors in the UK and US after admitting that it is investigating bribery allegations in several countries, legal experts have said.
GlaxoSmithKline and Theravance, Inc. today announced the start of a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid , fluticasone furoate and long-acting beta2 agonist , vilanterol .
Amid a relative dearth of economic data and the lack of fresh news in Ukraine, investors are focusing on the latest batch of U.S. corporate earnings and the slew of developments in the pharmaceuticals industry.
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Novartis shares are up 1.11% to $86.41 Novartis said it will buy GlaxoSmithKline's oncology products for $14.5 billion, and sell to GSK its vaccines, excluding flu, for $7.1 billion plus royalties.
Societe Generale has kept a 'sell' recommendation on AstraZeneca , questioning the reasoning behind a potential takeover by US pharmaceutical peer Pfizer.
Drug makers took center stage in European trading Tuesday, with shares of AstraZeneca PLC climbing on news of a potential takeover bid, and GlaxoSmithKline PLC rising as it sells one of its units in a multibillion-dollar deal.
In combining their consumer-health businesses, GlaxoSmithKline PLC and Novartis AG are creating a giant that unites some of the world's best-known brands.